Other
Liposomal Bupivacaine
0
Pipeline Programs↗
21
Active Trials↗
1
Companies Involved↗
Liposomal Bupivacaine is an early-stage landscape with 0 programs across 1 company. The most active players are Pacira Pharmaceuticals, Inc.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
100
clinical trials
Completed47 · 47%
Terminated15 · 15%
Recruiting14 · 14%
Unknown status10 · 10%
Withdrawn7 · 7%
Not yet recruiting3 · 3%
Other4 · 4%
Clinical Trials
Trial Activity
100 trials
Liposomal Bupivacaine Use in Alveolar Bone Graft Patients
Recruiting·—·Phase 3·NCT06284434·60 enrolled
The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery
Recruiting·—·N/A·NCT07458282·318 enrolled
The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Laparoscopic Surgery
Recruiting·—·N/A·NCT07458256·190 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)